Bottom line
XLV vs LOGSX: the short answer
XLV (State Street(R) Health Care Select Sector SPDR(R) ETF) and LOGSX (Live Oak Health Sciences Fund) are quite different portfolios: only about 31% of their top holdings (by weight) are shared.
But XLV is far broader, holding 65 positions to 28 for LOGSX, so beyond the top names it adds exposure LOGSX doesn't have.
XLV is cheaper at 0.08% vs 1.04% — a difference of $96 a year per $10,000 invested.
Over five years, LOGSX returned +8.1% a year vs +8.1% for XLV.
Updated Nov 19, 2026
XLV vs LOGSX side by side
| XLV | LOGSX | |
|---|---|---|
| Type | ETF | Mutual fund |
| Fund family | SPDR (State Street) | Oak Associates |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.08% | 1.04% |
| Annual cost per $10k | $8 | $104 |
| 10-yr cost on $10k (prospectus) | $103 | $1,271 |
| Max front load | None | — |
| 12b-1 fee | 0.02% | — |
| 1-yr return | +14.5% | +19.6% |
| 5-yr return (annualized) | +8.1% | +8.1% |
| 10-yr return (annualized) | +9.8% | +7.3% |
| Best quarter | +14.5% | +13.4% |
| Worst quarter | −12.7% | −13.1% |
| Net assets (fund) | $40.6B | $56.1M |
| Number of holdings | 65 | 28 |
| Portfolio turnover | 2% | 24% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | XLV | LOGSX | Difference |
|---|---|---|---|
| 2025 | +14.5% | +19.6% | −5.1% |
| 2024 | +2.5% | +0.2% | +2.3% |
| 2023 | +2.0% | +1.2% | +0.8% |
| 2022 | −2.1% | +3.7% | −5.8% |
| 2021 | +25.9% | +17.5% | +8.4% |
| 2020 | +13.3% | +6.0% | +7.3% |
| 2019 | +20.7% | +19.0% | +1.7% |
| 2018 | +6.3% | −4.0% | +10.2% |
| 2017 | +21.7% | +13.4% | +8.3% |
| 2016 | −2.8% | −0.4% | −2.5% |
Source: Fund prospectus bar charts
Holdings overlap
13 of XLV's top 25 holdings also appear in LOGSX's top 25.
| Holding | XLV | LOGSX |
|---|---|---|
| Eli Lilly & Co | 16.51% | 1.99% |
| Johnson & Johnson | 10.64% | 3.77% |
| Merck & Co Inc | 5.52% | 3.16% |
| Amgen Inc | 3.40% | 4.86% |
| Gilead Sciences Inc | 2.73% | 3.50% |
| Intuitive Surgical Inc | 2.45% | 2.99% |
| Vertex Pharmaceuticals Inc | 2.19% | 3.26% |
| Bristol-Myers Squibb Co | 2.05% | 4.02% |
| McKesson Corp | 1.58% | 4.53% |
| Cigna Group/The | 1.27% | 3.46% |
| Regeneron Pharmaceuticals Inc | 1.08% | 4.43% |
| Cardinal Health Inc | 0.97% | 5.86% |
| Cencora Inc | 0.96% | 4.46% |
Source: SEC Form N-PORT
XLV top 10
- Eli Lilly & Co — 16.51%
- Johnson & Johnson — 10.64%
- AbbVie Inc — 7.74%
- UnitedHealth Group Inc — 6.57%
- Merck & Co Inc — 5.52%
- Amgen Inc — 3.40%
- Thermo Fisher Scientific Inc — 3.24%
- Abbott Laboratories — 2.75%
- Gilead Sciences Inc — 2.73%
- Intuitive Surgical Inc — 2.45%
LOGSX top 10
- N/a — 6.91%
- Cardinal Health Inc — 5.86%
- Jazz Pharmaceuticals Plc — 5.77%
- United Therapeutics Corp — 5.11%
- Exelixis Inc — 4.95%
- Amgen Inc — 4.86%
- Lantheus Holdings Inc — 4.68%
- Novartis Ag — 4.67%
- Mckesson Corp — 4.53%
- Cencora Inc — 4.46%
FAQ
What is the difference between XLV and LOGSX?
Which is cheaper, XLV or LOGSX?
Should I own both XLV and LOGSX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.